Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 7613


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7613

License Grant
The Company is also entitled to royalty payments based on Prialt revenues
License Property
Prialt (ziconotide) is a non-narcotic intrathecal analgesic.
Field of Use
Prialt (ziconotide) is an atypical analgesic agent for the amelioration of severe and chronic pain.

IPSCIO Record ID: 5599

License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and  granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI).  It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 329681

License Grant
University hereby grants the License to the Licensee and its Affiliates  (i) an exclusive, worldwide right and license under the Patent Rights and (ii) a non-exclusive, worldwide right and license to the University Know-How to (a) make, have made, use, research, develop, have developed, lease, market, offer to sell, sell, have sold, distribute, improve, import and export Licensed Products and Licensed Processes in the Field; and (b) otherwise practice the Invention in the Field.
License Property
US Patent #6,248,744 – Method for the treatment of pain, including chronic and female specific pain.

Invention means University#98-14 Sex Related Deference in Pain Relief from Spinal Compound (RJR 2403)

VCU Patents  S Patent #5,914,337 – Compounds and pharmaceutical compositions thereof for eliciting analgesic effects

Field of Use
Field of use is for the treatment of pain relief.

TC-2696 for the treatment of chronic or female-specific pain.  TC-2696 is a novel small molecule that we are developing as an oral treatment for acute post-operative pain.

IPSCIO Record ID: 282861

License Grant
The Parties agree to collaborate and Licensor will provide product development services including analytical methods development and validation and formulation of a generic pharmaceutical product in the Territory.  Licensee will be responsible for the payment of costs and expenses incurred by the Collaboration Parties in connection with the  active pharmaceutical ingredients.
License Property
Product means the drug product to be mutually agreed upon by the parties that is a generic equivalent of a synthetic narcotic analgesic drug product.

Licensor is engaged in the research and development of generic pharmaceutical products and has accumulated  considerable knowledge in the field of pharmaceutical product development management services.

Field of Use
Narcotic agents are potent analgesics which are effective for the relief of severe pain. Analgesics are selective central nervous system depressants used to relieve pain. The term analgesic means 'without pain'.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.